Fluicell AB (publ) (STO:FLUI)
30.30
0.00 (0.00%)
Sep 24, 2026, 5:18 PM CET
Fluicell AB Employees
Fluicell AB had 11 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
11
Change
n/a
Growth
n/a
Revenue / Employee
1.68M SEK
Profits / Employee
254.55K SEK
Market Cap
41.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 11 | 0 | - |
| Mar 31, 2026 | 11 | 0 | - |
| Dec 31, 2025 | 11 | -1 | -7.38% |
| Sep 30, 2025 | 11 | 1 | 10.00% |
| Jun 30, 2025 | 11 | 0 | - |
| Mar 31, 2025 | 11 | -1 | -8.33% |
| Dec 31, 2024 | 12 | -4 | -23.75% |
| Sep 30, 2024 | 10 | -10 | -50.00% |
| Jun 30, 2024 | 11 | -9 | -45.00% |
| Mar 31, 2024 | 12 | -7 | -36.84% |
| Dec 31, 2023 | 16 | -2 | -11.11% |
| Sep 30, 2023 | 20 | 1 | 5.26% |
| Jun 30, 2023 | 20 | 2 | 11.11% |
| Mar 31, 2023 | 19 | 0 | - |
| Dec 31, 2022 | 18 | 2 | 12.50% |
| Sep 30, 2022 | 19 | 1 | 5.56% |
| Jun 30, 2022 | 18 | 0 | - |
| Mar 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Magle Chemoswed Holding AB | 150 |
| Biovica International AB | 24 |
| ExpreS2ion Biotech Holding AB | 19 |
| AcouSort AB | 11 |
| Ascelia Pharma AB | 10 |
| Alzinova AB | 7 |
| Spago Nanomedical AB | 6 |
| Annexin Pharmaceuticals AB | 4 |
Fluicell AB News
- 27 days ago - Fluicell AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Fluicell AB Quarterly report: Q1 2026 - Filings
- 7 months ago - Fluicell AB Annual report: Q4 2025 - Filings
- 7 months ago - Fluicell AB Quarterly report: Q4 2025 - Filings
- 10 months ago - Fluicell AB Quarterly report: Q3 2025 - Filings